Clinical characterization of cutaneous mucormycosis in patients receiving Bruton tyrosine kinase inhibitor therapy with Ibrutinib: A new case report and comparative discussion. (PubMed, Enferm Infecc Microbiol Clin (Engl Ed)) - Aug 2, 2026 - "Cutaneous mucormycosis is an emerging complication in Ibrutinib-treated patients. Early diagnosis and combined antifungal and surgical treatment are crucial."
Clinical • Journal • Review • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Oncology
|
|
Alfonso Gotor Rivera; Ana Pérez de Ayala Balzola; Borja Gonzalez Rodriguez; Concepción Postigo Llorente; Jorge Arroyo Andrés; José Luis Rodríguez Peralto
|